United States Health

RCM Technologies (NASDAQ:RCMT) reported second-quarter revenue of $93.8 million, up 20%, while GAAP net income rose to $4.9 million.

Pfizer (NYSE:PFE) and Valneva (NASDAQ:VALN) said the EMA validated their PF-07307405 Lyme vaccine application after Phase 3 efficacy exceeded 70%.

Rockwell Medical (NASDAQ:RMTI) reported second-quarter 2026 net sales of $17.8 million, up 11% year over year, as the healthcare company increased sales to new and existing dialysis customers.

Cullinan Therapeutics (NASDAQ:CGEM), Taiho Oncology, and Taiho Pharmaceutical announced that the global Phase 3 REZILIENT3 trial of zipalertinib plus platinum-based chemotherapy met its primary endpoint of progression-free survival in previously untreated patients with EGFR exon 20 insertion non-small cell lung cancer.

Belite Bio (NASDAQ:BLTE) reported second-quarter 2026 results and announced that the U.S. Food and Drug Administration accepted its New Drug Application for tinlarebant with Priority Review for Stargardt disease type 1.

Pharming (NASDAQ:PHAR) announced the commercial launch of Joenja (leniolisib) in Japan for patients aged 4 years and older with activated PI3K delta syndrome (APDS), following its inclusion on Japan’s National Health Insurance drug price list.

STAAR Surgical (NASDAQ:STAA) reported second-quarter 2026 net sales of $93.5 million, up 111% year over year, while net income improved to $8.1 million from a $16.8 million loss a year earlier.

Pharvaris (NASDAQ:PHVS) reported second-quarter 2026 results with cash and cash equivalents of €318 million as of June 30, 2026, while advancing clinical programs for its oral bradykinin B2 receptor antagonist deucrictibant.

Eloxx Pharmaceuticals (NASDAQ:ELOX) reported second-quarter 2026 results after completing a public offering that generated $66 million in gross proceeds and increased cash reserves to $62 million.

Kamada (NASDAQ:KMDA) reported second-quarter 2026 revenue of $54.9 million, up 23% year-over-year, with adjusted EBITDA of $14.1 million and net income of $9.3 million.

Liquidia (NASDAQ:LQDA) reported second-quarter 2026 revenue of $171.7 million, compared with $8.8 million a year earlier, driven mainly by YUTREPIA net product sales of $170.4 million.

Annexon (NASDAQ:ANNX) reported second-quarter 2026 financial results and clinical pipeline updates, including a net loss of $55.3 million, or $0.28 per share, for the quarter ended June 30, 2026.